Pharmacokinetics of third-generation aromatase inhibitors

摘要: The latest generation of nonsteroidal aromatase inhibitors (anastrozole and letrozole) has been approved by the US Food Drug Administration for use in first- second-line treatment postmenopausal women with hormone receptor-positive (or unknown) breast cancer. steroidal agent exemestane is currently being evaluated first line. In addition, these agents are adjuvant neoadjuvant settings. Because preclinical studies have suggested some differences efficacy to inhibit aromatase, it important evaluate whether properties actually translate into meaningful clinical setting. pharmacokinetic each inhibitor influences their ability perform effectively. Examination data suggests uptake rates, half-life elimination, metabolism, clearance rates that could influence efficacy. However, significance effectiveness over long-term remains be determined.